ImmPACT Bio Receives $8M from CIRM for Early-Stage Trial of Novel Dual-Target CAR T-Cell Treatment IMPT-514, Aimed at Tough-to-Treat Lupus Kidney Disease and Widespread Lupus Conditions.

Janux Therapeutics Reports Promising Preliminary Results on Tolerability and Therapeutic Impact in Progressive Dose Studies for Prostate Cancer Therapy JANX007 and Solid Cancer Treatment JANX008.

Alvotech and Teva have received FDA clearance for their product SIMLANDI® (adalimumab-ryvk), a novel substitutable biosimilar to Humira®.

Encoded Therapeutics Receives UK Regulatory Nod for Experimental Gene Treatment ETX101 Aimed at Dravet Syndrome.

Oscotec/Adel has commenced the initial human administration phase of their Phase 1 trial, testing the anti-tau antibody ADEL-Y01 as a potential treatment for Alzheimer's.

Immunofoco Reveals U.S. and China Regulators Grant Green Light to IND Submissions for Novel EpCAM CAR-T Therapy Aimed at Treating Severe Solid Cancers.

OncoC4 Reveals Initial Participant with Late-Stage Prostate Cancer Receives Dose in Early to Mid-Stage Study for BNT316/ONC-392, a Collaborative Effort with BioNTech.

Absci Begins Preclinical Studies on ABS-101, a New Leading Candidate for an Anti-TL1A Antibody, Created and Enhanced with Advanced AI Design Tools.

STORM Therapeutics will showcase research on its innovative METTL1 tRNA Methyltransferase blockers at the ESMO event for specialized cancer treatments.

FDA hastens assessment of a new application for Linvoseltamab, aimed at treating recurring or resistant forms of Multiple Myeloma.

ReCode Therapeutics Reports Initial Dosing of Subjects in Phase 1 Trial for Inhaled mRNA Therapy, RCT2100, Aimed at Cystic Fibrosis Treatment.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.